"Misją naszego Szpitala Wojewódzkiego w Opolu jest stworzenie szpitala przyjaznego Pacjentom. Pracujemy całą dobę, aby – w miarę możliwości – zapewnić każdemu Pacjentowi bezpieczne, szybkie diagnozowanie i profesjonalne leczenie."

During the past decade, Szpital Wojewodzki w Opolu conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 6 clinical trials were completed, i.e. on average, 31.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szpital Wojewodzki w Opolu" #1 sponsor was "BeiGene" with 3 trials, followed by "ADC Therapeutics S.A." with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Kartos Therapeutics, Inc." with 2 trials sponsored and "Rigel Pharmaceuticals" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Wojewodzki w Opolu" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Wojewodzki w Opolu" are "Chronic Lymphocytic Leukemia" (2 trials), "Immune Thrombocytopenic Purpura" (2 trials), "Primary Myelofibrosis (PMF)" (2 trials), "Chronic Idiopathic Constipation" (1 trials) and "Constipation" (1 trials). Many other conditions were trialed in "Szpital Wojewodzki w Opolu" in a lesser frequency.

Most popular intervention types in "Szpital Wojewodzki w Opolu" are "Drug" (20 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Rituximab" (3 trials), "Bendamustine" (2 trials), "Fostamatinib Disodium" (2 trials) and "KRT-232" (2 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Wojewodzki w Opolu" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Szpital Wojewodzki w Opolu". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Szpital Wojewodzki w Opolu, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Wojewodzki w Opolu, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Szpital Wojewodzki w Opolu has several departments that took part in Clinical trials: "Szpital Wojewodzki w Opolu, Oddzial Hematologii i Onkologii Hematologicznej" - 3 trials, "Department of Endocrinology, Szpital Wojewodzki w Opolu" - 2 trials